Manuel Rodrigues, Giulia Vanoni, Pierre Loap, Coraline Dubot, Eleonora Timperi, Mathieu Minsat, Louis Bazire, Catherine Durdux, Virginie Fourchotte, Enora Laas, Nicolas Pouget, Zahra Castel-Ajgal, Gregoire Marret, Laetitia Lesage, Didier Meseure, Anne Vincent-Salomon, Lolita Lecompte, Nicolas Servant, Sophie Vacher, Ivan Bieche, Caroline Malhaire, Virginie Huchet, Laurence Champion, Maud Kamal, Sebastian Amigorena, Olivier Lantz, Marion Chevrier, Emanuela Romano
Concurrent chemoradiotherapy (CRT) with blockade of the PD-1 pathway may enhance immune-mediated tumor control through increased phagocytosis, cell death, and antigen presentation. The NiCOL phase 1 trial (NCT03298893) is designed to determine the safety/tolerance profile and the recommended phase-II dose of nivolumab with and following concurrent CRT in 16 women with locally advanced cervical cancer. Secondary endpoints include objective response rate (ORR), progression free survival (PFS), disease free survival, and immune correlates of response...
June 22, 2023: Nature Communications